IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 Read more about Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference Read more about Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia Read more about XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia Ardelyx Announces Departure of Board Member Read more about Ardelyx Announces Departure of Board Member Ardelyx to Participate at the Jefferies London Healthcare Conference Read more about Ardelyx to Participate at the Jefferies London Healthcare Conference Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States Read more about Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 Read more about Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Read more about Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 Read more about Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference Read more about Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia Read more about XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
Ardelyx Announces Departure of Board Member Read more about Ardelyx Announces Departure of Board Member
Ardelyx to Participate at the Jefferies London Healthcare Conference Read more about Ardelyx to Participate at the Jefferies London Healthcare Conference
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States Read more about Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023 Read more about Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance Read more about Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance